Skip to content

Evaluating the effect of a goal-oriented comprehensive metabolic prevention (TCMP) model on comorbid risk and aging trajectory in elderly individuals living with HIV:A randomized controlled trial

A Study on Biomarkers of Aging and Co-Comorbidity Prevention in People Living with HIV

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123055
Enrollment
Unknown
Registered
2026-04-21
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Interventions

Control Group:Routine outpatient follow-up, monitoring HIV viral load, CD4 count, and basic metabolic indicators (such as fasting blood glucose, blood pressure, etc.) every 3 months, and managing abno
TCMP Group:1. Target value setting and dynamic management: (1) Five core metabolic targets: BMI (=2 items not met or medium-risk: Initiate drug intensification (such as adding metformin, statins),
Observation group (Cross-section):None

Sponsors

Chongqing Public Health Medical Treatment Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=50 years old; 2. HIV-infected individuals (diagnosed in accordance with the "Chinese AIDS Diagnosis and Treatment Guidelines (2024 Edition)"); 3. CD4+ >=200 cells/mm^3; 4. No concurrent chronic physical diseases (as per the "Expert Consensus on Coexistence of Multiple Diseases in the Elderly (2022)").

Exclusion criteria

Exclusion criteria: 1. Concurrent active opportunistic infections, including but not limited to: CMV infection, cryptococcal infection, AIDS-related tumors, tuberculosis, hepatitis B, hepatitis C, etc. 2. Active cancer was present within 12 months prior to entering the study. 3. Specific immunosuppressants or immunomodulators, including but not limited to tacrolimus, sirolimus, rapamycin, mycophenolate mofetil, cyclosporine, TNF-a blockers or antagonists, azathioprine, interferon, growth factors or intravenous immunoglobulin (IVIG), should be used within 30 days prior to the start of the study. 4. Currently, erythromycin, colchicine or rifampicin are being used. 5. Known active or recent (not completely cured within 30 days before enrollment) systemic bacterial, fungal, parasitic or viral infections.

Design outcomes

Primary

MeasureTime frame
Monitoring of metabolism-related indicators;Monitoring of aging indicators;

Secondary

MeasureTime frame
Verification of comorbidity status;

Countries

China

Contacts

Public ContactHuan Li

Chongqing Public Health Medical Center,

huangyinqiu917@163.com+86 158 2597 3506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026